HIV and AIDS: For health professionals
On this page
- What health professionals need to know about HIV and AIDS
- Disease progression
- Clinical manifestations
What health professionals need to know about HIV and AIDS
The human immunodeficiency virus (HIV) is a blood-borne infection that can be transmitted:
- to an unborn child during pregnancy or delivery
- through sharing substance use equipment
Acquired immune deficiency syndrome (AIDS) is a long-term sequela of infection.
Consider and discuss HIV testing as part of routine medical care. Early diagnosis and initiation of antiretroviral therapy (ART) can lead to reduced morbidity and mortality associated with:
- HIV infection
- disease progression to AIDS
Timely awareness of serostatus can reduce HIV transmission due to reduction in risk behaviour. In addition, ART reduces transmission. People who adhere to treatment and who achieve and maintain an undetectable viral load have effectively no risk of transmitting the infection sexually.
Pre-exposure prophylaxis (PrEP)
Pre-exposure prophylaxis (PrEP) is the use of prescription antiretroviral (ARV) medication by people who are HIV-negative, but at high risk for HIV infection. PrEP is used in combination with safer sex practices to lower the risk of HIV acquisition.
Taken before exposure, the medication interrupts HIV's ability to copy itself in the body and prevents it from establishing an infection.
Taking PrEP reduces the risk of getting sexually transmitted HIV by more than 90%. Participants in iPrEx and PrEP trials were:
- tested regularly for HIV and sexually transmitted infections (STIs)
- treated for STIs
- given condoms
PrEP is highly effective when taken correctly. Using condoms and other prevention methods along with PrEP can further reduce the risk of sexually acquired HIV.
In 2016, Health Canada granted market authorization of ARV (Emtricitabine, 200 mg, and Tenofovir Disoproxil Fumarate, 300 mg) for PrEP.
Health care providers should consult with an infectious disease specialist or a colleague experienced in HIV care to help:
- guide the patient assessment
- determine whether a benefit exists to initiate pre-exposure prophylaxis
Refer to the Health Canada regulatory decision summary for approved indications, benefits and risks related to PrEP.
Post-exposure prophylaxis (PEP) following recent exposure
Post-exposure prophylaxis (PEP) is the use of prescription ARV medication by people who are HIV-negative to lower the risk of HIV acquisition following a high-risk exposure. PEP should be started as soon as possible and is most effective when started within 72 hours of exposure. The decision to start PEP should be made jointly with the patient.
Health care providers should consult an infectious disease specialist or a colleague experienced in HIV care to help:
- guide the patient assessment
- determine whether a benefit exists to initiate PEP
Treatment as prevention (TasP)
Medications used to treat HIV can also prevent HIV transmission. People living with HIV who adhere to ART and who achieve and maintain an undetectable viral load have effectively no risk of transmitting HIV sexually.
Treatment as prevention (TasP) is an important prevention strategy. Discuss the benefits of ART as part of routine HIV care.
The amount of time from initial infection to the development of clinical manifestations is highly variable, as is disease progression.
HIV infection results in the progressive destruction of CD4+ T lymphocytes. These white blood cells are crucial to the normal function of the immune system.
Consequently, people with HIV and subsequent immune suppression are at risk of developing a variety of AIDS-defining conditions, including:
- opportunistic infections
- primary neurologic disease
Due to advances in HIV treatment:
- the progression of the disease has slowed to a great degree
- HIV infection is considered a chronic, treatable condition
Depending on the stage of infection, people with HIV may be asymptomatic, or may present with:
- non-specific symptoms that may not be recognized as HIV infection
- various signs and symptoms related to immunodeficiency
Primary acute infection
This is the period from initial infection to development of the full serum antibody profile (seroconversion).
Up to 90% of patients in the acute infection stage are symptomatic.
Clinicians should remain vigilant, as misdiagnosis of acute infection is common and there is a high risk of transmission at this stage. Clinicians should include HIV infection in the differential diagnosis and test for HIV when someone presents with a:
- non-specific febrile illness and/or
- history of high-risk behaviour
If present, symptoms:
- generally appear 2 to 6 weeks after exposure
- are usually self-limited
- generally last 1 to 2 weeks, although some may last several months
- are similar to those of many other illnesses, including viral syndromes, such as:
The symptoms of acute retroviral syndrome include:
- sore throat
Chronic asymptomatic infection
In this stage:
- viral replication and plasma viremia are more controlled by the immune response represented by the level of CD4+ T cells
- generalized lymphadenopathy is frequently present
- thrombocytopenia may be present
- there’s a decreased risk of transmission
Many individuals with HIV infection fall into this category.
Chronic symptomatic infection
In this stage, the disease is characterized by:
- high levels of:
- viral replication
- plasma viremia
- increased risk of transmission
- a depressed CD4+ T cell count
- viral shedding from mucosal sites
Viral replication depletes the CD4+ T cells to the level of profound immunosuppression, leading to opportunistic infections.
Different types of HIV screening tests are licensed for use in Canada. Type and availability can vary by jurisdiction.
Approach to testing
Before offering an HIV test, conduct an assessment and ensure the individual understands:
- how HIV is transmitted
- the implications of testing (advantages and disadvantages)
- how to interpret the test results
An HIV test can be offered without in-depth behaviour-based risk assessment and/or extensive pre- and post-test counselling.
The detection of the HIV antibody is the most widely used means of diagnosing HIV.
The window period is the time after acquisition of HIV, when the:
- risk of transmission is high but
- individuals test negative on HIV antibody screening, because antibodies aren’t immediately produced or detectable
The length of the window period varies with the test used. Of the 2 main types of tests:
- third-generation HIV enzyme immunoassay (EIA) antibody tests:
- are able to detect the antibody in 99% of people 3 months after exposure
- may detect the antibody as early as 20 to 30 days after exposure in some individuals
- fourth-generation combination tests:
- also permit the detection of p24 antigen during the acute phase of infection
- reduce the window period to between 15 and 20 days
HIV infection can also be diagnosed by detecting the presence of the virus itself through the following tests.
- Qualitative viral detection tests (NAAT) and/or quantitative NAAT (viral load testing) can be used under certain circumstances.
- Genotyping and phenotyping are also used for monitoring HIV drug resistance.
Advances in HIV treatment:
- have slowed disease progression to such a degree that HIV infection is considered a chronic, treatable condition
- are enabling more people with HIV to live healthy, long and active lives
Early diagnosis and treatment can lead to reduced morbidity and mortality associated with HIV infection and disease progression.
Treatment of HIV is a rapidly evolving and complex area, with changes in optimal therapy occurring as new research and evidence becomes available. If ART is being considered, consult a colleague experienced in HIV/AIDS care or an infectious diseases specialist. Your local public health authority will have a listing of these health professionals.
Effective ART can be an important prevention strategy. People who adhere to ART and who achieve and maintain an undetectable viral load have effectively no risk of transmitting HIV sexually. Effective ART can also help prevent the vertical transmission of HIV.
Undetectable = Untransmittable (U = U)
U = U reflects the scientific evidence that someone who is being treated for HIV and who achieves and maintains an undetectable viral load has effectively no risk of transmitting HIV sexually. Refer to the HIV U = U factsheet.
Health care providers should encourage the consistent and correct use of condoms to prevent the acquisition or transmission of other STIs.
Health care providers should:
- follow the guiding principles of the HIV screening and testing guide
- tailor testing approaches to:
- reduce barriers to HIV testing
- meet the needs of their patients
- provide culturally appropriate and gender-responsive care
Health professionals in Canada play a critical role in identifying and reporting cases of HIV/AIDS.
People living with HIV in Canada
At the end of 2016, the estimated number of persons living with HIV in Canada was 63,110 (plausible range 55,500 to 70,720).
An estimated 1 in 7 Canadians who has HIV hasn’t been diagnosed and is unaware of the infection.
In the same year, an estimated 2,165 new HIV infections occurred in Canada (plausible range between 1,200 and 3,150).
People living with HIV around the world
The World Health Organization's Global Health Observatory provides data on HIV and AIDS around the world. It estimates that about 37 million people were living with HIV at the end of 2016.
Surveillance of HIV and AIDS
HIV and AIDS are both notifiable diseases. The national notification system is voluntary and receives cases reported through provincial or territorial departments of health.
Provinces and territories have provincial or territorial legislation for the reporting of priority infectious diseases within their jurisdictions. All provinces and territories report newly diagnosed cases of HIV to the federal department. However, not all provinces and territories have mandatory reporting of AIDS.
- HIV/AIDS in Canada (video)
- HIV in Canada: 2018 surveillance highlights (infographic)
- HIV in Canada: Canada's progress to meet HIV 90-90-90 targets by 2020 (infographic)
- Take an Active Approach to Sexually Transmitted and Blood-Borne Infections (STBBI) Testing (infographic)
- Human Immunodeficiency Virus (HIV) Screening and Testing Guide
- Canadian Guidelines on Sexually Transmitted Infections (includes downloadable mobile application)
Canada Communicable Disease Report
- HIV in Canada: Surveillance Report, 2016
- A Review of Human Immunodeficiency Virus (HIV) Rapid Testing
- A Synopsis of the Current Evidence on the Risk of HIV Transmission
- An Overview of Recent Evidence on Barriers and Facilitators to HIV testing
- Synopsis of the Human Immunodeficiency Virus (HIV) Screening and Testing Guide
- Canadian Results from the 2017 EMIS (European Men-who-have-sex-with-men Internet Survey)
- Canadian and International Recommendations on the Frequency of HIV Screening and Testing: A Systematic Review
- Summary: Estimates of HIV Prevalence and Incidence in Canada, 2016
- Update on HIV-1 Strain and Transmitted Drug Resistance in Canada: 2012–2013
- I-Track: Enhanced surveillance of HIV, hepatitis C, and associated risk behaviours among people who inject drugs in Canada. Phase 3 (2010–2012) Report
- Summary of Key Findings from Y-Track Phase 6 (2009–2012)
- CATIE's fact sheet on oral pre-exposure prophylaxis (PrEP)
- Use of Early Antiretroviral Therapy in HIV-infected Persons (PDF)
- European Men-Who-Have-Sex-with-Men Internet Survey (EMIS-2017)
- WHO Implementation Tool for Pre-Exposure Prophylaxis (PrEP) of HIV infection
- Society of Obstetricians and Gynaecologists: Canadian HIV Pregnancy Planning Guidelines
- Canadian Guideline on HIV Pre-exposure Prophylaxis and Nonoccupational Postexposure Prophylaxis
Report a problem or mistake on this page
- Date modified: